The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Zukov R.A.
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Center;
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Zyuzyukina A.V.
A.I. Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology Dispensary
Batukhtina Yu.V.
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Center;
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Komissarova V.A.
A.I. Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology Dispensary
Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer
Journal: P.A. Herzen Journal of Oncology. 2023;12(3): 34‑41
Read: 1896 times
To cite this article:
Fateeva AV, Zukov RA, Zyuzyukina AV, et al. . Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer. P.A. Herzen Journal of Oncology.
2023;12(3):34‑41. (In Russ.)
https://doi.org/10.17116/onkolog20231203134
The selective CDK4/6 inhibitors palbociclib and ribociclib, which have appeared in the practice of a Russian clinician, have changed the paradigm of treatment in patients with HR+/HER2 breast cancer. The candidates for this therapy may also become patients who have previously been recommended chemotherapy due to the high prevalence of the disease and those with the threat of a visceral crisis. A controlled safety profile is a significant argument in favor of choosing tactics for the use of CDK4/6.
To identify potential predictors for the efficiency of CDK4/6 inhibitor therapy in real clinical practice.
The authors retrospectively studied a database involving 170 patients with metastatic HR+/HER2 breast cancer who were treated with palbociclib and ribociclib in combination with any-line endocrine therapy from 2019 to June 2020 in five oncology dispensaries in Siberia and the Far East. They examined the influence of leukopenia and other factors on the duration of combination endocrinotherapy, as well as the relationship of disease progression to the severity adverse events. The end point was the estimation of the duration of therapy with CDK4/6 inhibitors, depending on the factors studied. Calculations were done using the Kolmogorov-Smirnov criterion, the Spearman correlation coefficient, the Mann-Whitney test, the Pearson χ2 test. The time to progression was estimated by the Kaplan-Meyer method. (see p. 12 and the article),
In the group of patients with the leukopenia degree (of less than 1.000 to 2.9 thousand cells/µl) registered during palbociclib or ribociclib treatment; the median time to progression was 35 months compared to a group of patients who were not observed to have leukopenia or a recorded white blood cell levels of not less than 3 thousand cells/µl; the median progression-free time was 24 months.
The leukopenia degree of less than 1.000 to 2.9 thousand cells/µl can be potentially a factor of a longer duration and a marker for the efficiency of therapy with the CDK4/6 inhibitors in the treatment of metastatic HR+/HER2 in the treatment of metastatic HR+HER2 breast cancer.
Keywords:
Authors:
Zukov R.A.
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Center;
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Zyuzyukina A.V.
A.I. Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology Dispensary
Batukhtina Yu.V.
A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Center;
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Komissarova V.A.
A.I. Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology Dispensary
Received:
20.04.2023
Accepted:
18.05.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.